Free Trial
NASDAQ:OCS

Oculis Q4 2024 Earnings Report

Oculis logo
$17.84 -0.10 (-0.53%)
As of 02:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Oculis EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.28
One Year Ago EPS
N/A

Oculis Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.21 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oculis Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 11, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Oculis' Q2 2025 earnings is scheduled for Tuesday, August 26, 2025

Oculis Earnings Headlines

Your blueprint for crypto wealth
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

View Oculis Profile

More Earnings Resources from MarketBeat